The Challenge to Patent Law of Pure Chemical Protein Synthesis

Nature Biotechology, Vol. 23, No. 5

Posted: 7 May 2005

See all articles by Aaron Xavier Fellmeth

Aaron Xavier Fellmeth

Arizona State University (ASU) - Sandra Day O'Connor College of Law

Abstract

This article argues that the emergence of pure chemical protein synthesis as a commercially viable method of drug design and production will create serious problems in the patent system and explains why. Patents on recombinant proteins will block research on and the commercialization of these same proteins produced through chemical synthesis, with accompanying negative effects for medical research. This looming problem illustrates why patents on naturally occurring proteins should not be granted. In the future, chemists must now focus on modifying such natural proteins to avoid the patents.

Keywords: Patent law, biotechnology

Suggested Citation

Fellmeth, Aaron Xavier, The Challenge to Patent Law of Pure Chemical Protein Synthesis. Nature Biotechology, Vol. 23, No. 5, Available at SSRN: https://ssrn.com/abstract=715341

Aaron Xavier Fellmeth (Contact Author)

Arizona State University (ASU) - Sandra Day O'Connor College of Law ( email )

Box 877906
Tempe, AZ 85287-7906
United States

Do you have negative results from your research you’d like to share?

Paper statistics

Abstract Views
1,073
PlumX Metrics